AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25515163 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical method of esophageal speech therapy
Number of subjects: 26
Study 25515163 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified animation of air movements method using MII
Number of subjects: 26
Study 25515163 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Classical and Simplified methods)
Number of subjects: 26
Study 25619206 — intervention group
Group type: EXPERIMENTAL
Intervention: Everted closure using interrupted subcuticular sutures
Number of subjects: 0
Study 25619206 — intervention group
Group type: COMPARATOR
Intervention: Planar closure
Number of subjects: 0
Study 23808506 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (bolus of 8 to 15 ml of ropivacaine 0.2% and infusion of 5 to 15 ml/hour for three days)
Number of subjects: 42
Study 23808506 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block (bolus dose of 20 ml of ropivacaine 0.375% bilaterally and infusion of 0.2% ropivacaine 8 ml/hour bilaterally for three days)
Number of subjects: 42
Study 20623443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-free diet (FFD) with polyethylene glycol electrolyte solution (PEG-ES)
Number of subjects: 200
Study 20623443 — intervention group
Group type: COMPARATOR
Intervention: Clear-liquid diet (CLD) with polyethylene glycol electrolyte solution (PEG-ES)
Number of subjects: 200
Study 18972726 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance-partitioned moxibustion
Number of subjects: 209
Study 18972726 — intervention group
Group type: COMPARATOR
Intervention: Chinese drug Yueyue-shu (Control)
Number of subjects: 209
Study 16377669 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg) alone
Number of subjects: 18
Study 16377669 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (600 mg) with antacid (Maalox containing 600 mg magnesium hydroxide and 900 mg aluminum hydroxide)
Number of subjects: 18
Study 12754130 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 12.3±3.6 mg once a week + Meloxicam 7.5 mg for 3 months
Number of subjects: 32
Study 12754130 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 21.3±3.2 mg once a week + Meloxicam 7.5 mg for 3 months
Number of subjects: 32
Study 10780764 — intervention group
Group type: EXPERIMENTAL
Intervention: Air pollution exposure in road tunnel (NO2 levels > or = 300 microg x m‐3)
Number of subjects: 20
Study 10780764 — intervention group
Group type: EXPERIMENTAL
Intervention: Air pollution exposure in road tunnel (PM2.5 levels > or = 100 microg x m‐3)
Number of subjects: 20
Study 10780764 — intervention group
Group type: COMPARATOR
Intervention: Control exposure in suburban area (lower pollution levels)
Number of subjects: 20
Study 8967757 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg/day rhCNTF
Number of subjects: 570
Study 8967757 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg/day rhCNTF
Number of subjects: 570
Study 8967757 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg/day rhCNTF
Number of subjects: 570
Study 8967757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 1330676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (0.5 mg/ml)
Number of subjects: 10
Study 1330676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2.5 mg/ml)
Number of subjects: 10
Study 1330676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (10 mg/ml)
Number of subjects: 10
Study 1330676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31095117 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL 0.5% ropivacaine and 1 ug/kg of dexmedetomidine (group RD)
Number of subjects: 57
Study 31095117 — intervention group
Group type: COMPARATOR
Intervention: 20 mL 0.5% ropivacaine (group R)
Number of subjects: 57
Study 28339165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate nasal spray
Number of subjects: 55
Study 28339165 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 55
Study 25859431 — intervention group
Group type: EXPERIMENTAL
Intervention: ReCog intervention
Number of subjects: 29
Study 25859431 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 29
Study 23876559 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) at 25Hz and peak to peak displacement of 4mm
Number of subjects: 23
Study 23876559 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 23
Study 23876559 — intervention group
Group type: COMPARATOR
Intervention: No Whole Body Vibration (noWBV)
Number of subjects: 23
Study 22356951 — intervention group
Group type: EXPERIMENTAL
Intervention: White obese avatar
Number of subjects: 128
Study 22356951 — intervention group
Group type: EXPERIMENTAL
Intervention: Black obese avatar
Number of subjects: 128
Study 22356951 — intervention group
Group type: COMPARATOR
Intervention: White thin avatar
Number of subjects: 128
Study 22356951 — intervention group
Group type: COMPARATOR
Intervention: Black thin avatar
Number of subjects: 128
Study 19204523 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior trauma history
Number of subjects: 1167
Study 19204523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime psychiatric history
Number of subjects: 1167
Study 19204523 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintentional injury survivors with psychiatric history
Number of subjects: 1167
Study 17666926 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing
Number of subjects: 225
Study 17666926 — intervention group
Group type: COMPARATOR
Intervention: Routine laboratory analysis
Number of subjects: 225
Study 16216821 — intervention group
Group type: EXPERIMENTAL
Intervention: Self management using a point of care device to measure INR twice a week and a dosing chart
Number of subjects: 617
Study 16216821 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 617
Study 16216821 — intervention group
Group type: EXPERIMENTAL
Intervention: Self management
Number of subjects: 617
Study 14589256 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care plus physical therapy
Number of subjects: 681
Study 14589256 — intervention group
Group type: COMPARATOR
Intervention: Medical care only
Number of subjects: 681
Study 14589256 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care with physical modalities
Number of subjects: 681
Study 14589256 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care without physical modalities
Number of subjects: 681
Study 14589256 — intervention group
Group type: COMPARATOR
Intervention: Medical care without physical therapy
Number of subjects: 681
Study 10541320 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal vasculitis
Number of subjects: 1078
Study 10541320 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal receipt of antibiotic in the 24 hours before delivery
Number of subjects: 1078
Study 10541320 — intervention group
Group type: COMPARATOR
Intervention: Placental membrane inflammation
Number of subjects: 1078
Study 7698572 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 413
Study 7698572 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental formulas
Number of subjects: 413
Study 7698572 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 413
Study 2339012 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 5 mg/kg
Number of subjects: 7
Study 2339012 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 7
Study 526397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of labetalol
Number of subjects: 12
Study 526397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of labetalol
Number of subjects: 12
Study 526397 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of labetalol
Number of subjects: 12
Study 31705466 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention, including the provision of a home BP monitor
Number of subjects: 159
Study 31705466 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW plus additional training in shared decision-making skills (DoMyPART)
Number of subjects: 159
Study 31705466 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW plus additional training in self-management problem-solving (Problem Solving)
Number of subjects: 159
Study 31705466 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 159
Study 30998227 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) diet consultations with individualized dietary glycemic load assessments using an app.
Number of subjects: 400
Study 30998227 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary education according to the Chinese Dietary Guide for Pregnant Women (Control).
Number of subjects: 400
Study 28814393 — intervention group
Group type: EXPERIMENTAL
Intervention: FSMS-RUTF
Number of subjects: 0
Study 28814393 — intervention group
Group type: EXPERIMENTAL
Intervention: MSMS-RUTF
Number of subjects: 0
Study 28814393 — intervention group
Group type: COMPARATOR
Intervention: PM-RUTF
Number of subjects: 0
Study 25798601 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% of maximal sprint velocity with supervision (90SUP, n = 10)
Number of subjects: 45
Study 25798601 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% intensity without supervision (100UNSUP, n = 13)
Number of subjects: 45
Study 25798601 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% of maximal sprint velocity without supervision (90UNSUP, n = 13)
Number of subjects: 45
Study 25798601 — intervention group
Group type: COMPARATOR
Intervention: Regular soccer training (Control group, CON, n = 9)
Number of subjects: 45
Study 24197584 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan therapy
Number of subjects: 30
Study 24197584 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 20715906 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt and bread enriched with biologically active substances
Number of subjects: 80
Study 20715906 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group II)
Number of subjects: 80
Study 19187340 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(2) infusion (0.40 microg kg(‐1) min(‐1))
Number of subjects: 11
Study 19187340 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 11
Study 16731393 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior midline point stop (AMPS) device
Number of subjects: 114
Study 16731393 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-arch stabilization splint
Number of subjects: 114
Study 16731393 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 15588139 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer (CaB)
Number of subjects: 183
Study 15588139 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer (CaC)
Number of subjects: 183
Study 15588139 — intervention group
Group type: COMPARATOR
Intervention: Control group (without oncological diseases)
Number of subjects: 183
Study 11536222 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release (MR) dosage forms of metformin
Number of subjects: 8
Study 11536222 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) dosage forms of metformin
Number of subjects: 8
Study 11536222 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release (MR) formulations of metformin
Number of subjects: 8
Study 11536222 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic convolution level A model using in vitro dissolution as in vivo input
Number of subjects: 8
Study 11536222 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended convolution approach modeling absorption using a Hill function
Number of subjects: 8
Study 9340970 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum containing re‐induction chemotherapy
Number of subjects: 0
Study 9340970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment (tamoxifen or GnRH analogues)
Number of subjects: 0
Study 9340970 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with topoisomerase blocking agents, taxanes, or alkylating agents
Number of subjects: 0
Study 9340970 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8485203 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (tretinoin) for AML M3
Number of subjects: 594
Study 8485203 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for AML M4Eo
Number of subjects: 594
Study 8485203 — intervention group
Group type: COMPARATOR
Intervention: Other FAB types combined
Number of subjects: 594
Study 3691693 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveally stabilized target on a dark field
Number of subjects: 6
Study 3691693 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveally stabilized point target on a sinusoidally moving non‐stabilized background
Number of subjects: 6
Study 3691693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudo‐random background movement
Number of subjects: 6
Study 29885390 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support for GDM care
Number of subjects: 95
Study 29885390 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 95
Study 26417057 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth differentiation factor-15 (GDF-15) levels
Number of subjects: 16876
Study 24614012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 80
Study 24614012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23528580 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (375 mg daily)
Number of subjects: 70
Study 23528580 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants (fevarin 150 mg daily)
Number of subjects: 70
Study 20434674 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgery
Number of subjects: 59
Study 20434674 — intervention group
Group type: COMPARATOR
Intervention: Standard sharp debridement (Control)
Number of subjects: 59
Study 18950383 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dose of amitriptyline
Number of subjects: 17
Study 16192503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavitation Ultrasonic Surgical Aspirator (CUSA)
Number of subjects: 50
Study 16192503 — intervention group
Group type: COMPARATOR
Intervention: Clamp‐crushing method (CC group)
Number of subjects: 50
Study 12452403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis treatment (seven biweekly sessions and home audiotapes)
Number of subjects: 42
Study 12452403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis treatment
Number of subjects: 42
Study 10599010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counselling at the start of treatment and at each subsequent visit for ambulatory patients, or weekly for hospitalised patients.
Number of subjects: 1019
Study 10599010 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1019
Study 10599010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counselling (intervention).
Number of subjects: 1019
Study 7627507 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion using Haemocell S‐350 device
Number of subjects: 17
Study 7627507 — intervention group
Group type: COMPARATOR
Intervention: Bank blood control
Number of subjects: 17
Study 7627507 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6‐micron pore size filter
Number of subjects: 17
Study 1773490 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbidimetric assay
Number of subjects: 46
Study 1773490 — intervention group
Group type: EXPERIMENTAL
Intervention: All assays (including turbidimetric, Kodak, Poli, and immunochemical)
Number of subjects: 46
Study 1773490 — intervention group
Group type: COMPARATOR
Intervention: Turbidimetric procedure from Boehringer, two enzymatic approaches from Kodak and Poli, and an immunochemical assay
Number of subjects: 46
Study 7075566 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cleansing enemas
Number of subjects: 93
Study 7075566 — intervention group
Group type: COMPARATOR
Intervention: New simpler oral cleansing preparation
Number of subjects: 93
Study 31962346 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment for primary headache (8-11 sessions, including vasoconstriction/vasodilation training for migraine and electromyography training for tension-type headache)
Number of subjects: 70
Study 31962346 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (no treatment)
Number of subjects: 70
Study 29985874 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (EES) at a dose of 50 mg . kg . day
Number of subjects: 43
Study 29985874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 27684813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based box trainer (TBT)
Number of subjects: 32
Study 27684813 — intervention group
Group type: COMPARATOR
Intervention: Standard box trainer (SBT)
Number of subjects: 32
Study 24909799 — intervention group
Group type: EXPERIMENTAL
Intervention: β-cryptoxanthin (0.75 mg/day) plus phytosterols (1.5 g/day)
Number of subjects: 38
Study 24909799 — intervention group
Group type: EXPERIMENTAL
Intervention: β-cryptoxanthin (0.75 mg/day)
Number of subjects: 38
Study 24909799 — intervention group
Group type: EXPERIMENTAL
Intervention: phytosterols (1.5 g/day)
Number of subjects: 38
Study 24909799 — intervention group
Group type: EXPERIMENTAL
Intervention: β-cryptoxanthin plus phytosterols
Number of subjects: 38
Study 23043951 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F (PGF) 2 mL per fish in 2009/2010 season and 5 mL per fish in 2010/2011 season, in addition to carp pituitary extract (6 mg/kg)
Number of subjects: 45
Study 23043951 — intervention group
Group type: COMPARATOR
Intervention: Carp pituitary extract (6 mg/kg)
Number of subjects: 45
Study 23043951 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F (PGF)
Number of subjects: 45
Study 23043951 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F (PGF) and carp pituitary extract
Number of subjects: 45
Study 20629111 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 88
Study 19002089 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 set of progressive resistance exercises
Number of subjects: 100
Study 19002089 — intervention group
Group type: COMPARATOR
Intervention: 2 sets of progressive resistance exercises
Number of subjects: 100
Study 16463827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial pressure > 20 mmHg
Number of subjects: 36
Study 16463827 — intervention group
Group type: COMPARATOR
Intervention: Intracranial pressure < 20 mmHg
Number of subjects: 36
Study 16463827 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 after SAH
Number of subjects: 36
Study 12431041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate .025% ophthalmic solution
Number of subjects: 495
Study 12431041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study 10875870 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation of the first polar body at 6 o'clock
Number of subjects: 114
Study 10875870 — intervention group
Group type: COMPARATOR
Intervention: Orientation of the first polar body at 12 o'clock
Number of subjects: 114
Study 8575972 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated cows
Number of subjects: 52
Study 8575972 — intervention group
Group type: EXPERIMENTAL
Intervention: Calves from vaccinated cows
Number of subjects: 52
Study 8575972 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatally vaccinated calves
Number of subjects: 52
Study 8575972 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated calves
Number of subjects: 52
Study 1299590 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic treatment only (Group A)
Number of subjects: 98
Study 1299590 — intervention group
Group type: COMPARATOR
Intervention: 3 g GL intravenously 15 min before thrombolysis (Group B)
Number of subjects: 98
Study 1299590 — intervention group
Group type: COMPARATOR
Intervention: 6.25 mg CA orally 15 min before thrombolytic treatment (Group C)
Number of subjects: 98
Study 1299590 — intervention group
Group type: COMPARATOR
Intervention: 3 g GL intravenously before thrombolysis and 6.25 mg CA orally (Group D)
Number of subjects: 98
Study 6380554 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bd tamoxifen
Number of subjects: 263
Study 6380554 — intervention group
Group type: COMPARATOR
Intervention: 20 mg bd tamoxifen
Number of subjects: 263
Study 31188062 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotions with low cognitive resources
Number of subjects: 174
Study 31188062 — intervention group
Group type: COMPARATOR
Intervention: Neutral emotions with low cognitive resources
Number of subjects: 174
Study 31188062 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotions with high cognitive resources
Number of subjects: 174
Study 31188062 — intervention group
Group type: COMPARATOR
Intervention: Neutral emotions with high cognitive resources
Number of subjects: 174
Study 29901816 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet for 12 weeks
Number of subjects: 75
Study 29901816 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (control group)
Number of subjects: 75
Study 27156934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg subcutaneously weekly
Number of subjects: 87
Study 27156934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 27156934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 87
Study 1330565 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single-dose)
Number of subjects: 60
Study 1330565 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (seven-day course)
Number of subjects: 60
Study 22800352 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-acid therapy and conventional pharyngo-laryngitis therapy in LPR group
Number of subjects: 34
Study 22800352 — intervention group
Group type: COMPARATOR
Intervention: Anti-acid therapy and conventional pharyngo-laryngitis therapy in control group
Number of subjects: 34